Interview with Francisco Piccolo, President, Biogen Idec Brazil
When we spoke with Mr. Barbano at ANVISA, he mentioned RDC 55/10 and his hopes that it will do for the biologics market what the generics law of 1999 did…
Company Profile
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as multiple sclerosis (MS), lymphoma and rheumatoid arthritis. In 2008, Biogen Idec’s total revenues grew 29 percent over 2007 to $4.1 billion. Biogen Idec is headquartered in Cambridge, Massachusetts, with international headquarters in Zug, Switzerland. They have additional offices in the US, Canada, Australia, Japan and throughout Europe. Biogen Idec has a direct commercial presence in 29 markets, a network of distribution partners in more than 70 additional markets and operations in several new markets, including Central/Eastern Europe, Brazil, China and India.
Contact Info
Biogen Idec Brasil Produtos
Farmacêuticos Ltda.
Edifício Olimpia Trade
Av. Dr. Cardoso de Melo, 1.184,
17º andar,
Vila Olimpia- São Paulo-SP,
CEP; 04548-004
Brazil
Phone: +55 11 3568 3400
Fax: +55 11 3568 3440
www.biogenidec.com.br
When we spoke with Mr. Barbano at ANVISA, he mentioned RDC 55/10 and his hopes that it will do for the biologics market what the generics law of 1999 did…
After international tenures in Korea and at Servier’s global headquarters in Paris, Matthieu Mendil has taken the helm of Servier Brazil at a pivotal moment in the affiliate’s evolution. Drawing…
Rogerio Frabetti, General Manager of Biogen Brazil discusses the organisation’s strategic transformation as it expands beyond its neuroscience heritage into immunology whilst maintaining leadership in rare diseases. He articulates Brazil’s…
Rolf Hoenger discusses Roche LATAM’s growth, emphasising patient-centric strategies, untapped access potential, and evidence-based dialogue with policymakers. He highlights accelerated regulatory approvals, digital health initiatives, and Movement Health Foundation projects,…
Roberto Alvarenga, VP at Biotronik’s Latin American operations, reflects on the company’s six decades of innovation and LatAm’s emergence as the firm’s fastest-growing region. He outlines a strategy focused on…
Vaccination remains the most powerful public health intervention ever devised, preventing an estimated 4.4 million deaths each year, according to the WHO. Yet with misinformation spreading faster than science, and…
Adium is one of Latin America’s most expansive pharmaceutical groups, operating across 18 countries with a workforce of 7,000 employees. The organisation has unified its brand identity across the region…
Sylvester Feddes, Country President of Novartis Brazil, outlines the country’s rise as a top global market driven by strong public-private healthcare infrastructure and vast unmet needs. With nearly 100 active…
Sinan Atlig reflects on a 25-year global career spanning Turkey, Colombia, the Middle East, and the US, shaped decisively by vaccine leadership through the COVID-19 era. He identifies vaccines and…
As one of Brazil’s leading pharmaceutical powerhouses, CIMED has redefined what it means to be both national and innovative. Built on a fully verticalised model that spans from R&D to…
Dr Jarbas Barbosa, Director of the Pan American Health Organization (PAHO), discusses the organisation’s evolution from pandemic response to comprehensive health system transformation, regional production capabilities, and the imperative for…
As Latin America’s largest pharma market, worth USD 62 billion in 2024, Brazil is retooling its industry to meet new demands. Driven by changing demographics, chronic disease burdens, and the…
Brazil’s pharmaceutical sector is undergoing a quiet but significant transformation. Once dominated by multinationals and focused largely on generics, a group of leading domestic players is now charting a different…
See our Cookie Privacy Policy Here
